Guangzhou Innogen Pharmaceutical Group Co., Ltd. (stock code: 02591) released its monthly return for equity securities as of January 31, 2026. According to the announcement, the total authorized share capital remained at RMB 456,819,349, divided between 420,285,370 H shares and 36,533,979 unlisted shares. No changes in authorized share capital were recorded during the month.

The number of issued H shares was 420,285,370, with no treasury shares and no movement in share count for the period. The unlisted ordinary shares remained at 36,533,979, also with no changes. The public float requirements were met, reflecting compliance with the minimum public float threshold of 25%.

No share options, warrants, or convertible securities were reported, and there were no other notable share issuances or cancellations during this period. The monthly return was submitted by the company’s Joint Company Secretary on February 3, 2026.